An Oral Glucose Tolerance Test (OGTT) is when you drink a sugary drink to show if your body makes enough insulin to cover the amount of glucose you would get in a regular meal. If your body can’t, it may mean that diabetes is starting to develop.
We anticipate that screening will eventually become part of routine medical care. However, before that happens, most likely there will need to be a proven therapy in place to prevent T1D. Until then, we expect to continue TrialNet screening. But don’t wait to participate—find out your risk and help us find a way to stop T1D!
Detecting the disease in its earliest stage—before symptoms—allows for prompt intervention. TrialNet screening looks for diabetes-related autoantibodies that can be identified years before symptoms appear. The JDRF, ADA, and Endocrine Society now classify having two or more of these autoantibodies as early stage T1D. Research shows that nearly all individuals who have two or more of these autoantibodies will develop T1D. Finding these autoantibodies early can give you the opportunity to change the course of the disease.
You may be eligible for future prevention trials. TrialNet will let you know when new trials are available.
Results are available after 6 weeks (8 weeks internationally). You will receive a letter in the mail if your test results are negative for autoantibodies. Participants who test positive will receive a phone call from their study team to discuss next steps.
If your child has two or more autoantibodies, the likelihood of developing T1D nears 100%. Detecting the disease in its earliest stage gives you the opportunity to change the course of the disease. TrialNet offers clinical trials testing ways to slow or stop the disease at every stage. We also provide close monitoring.
No. Your results are strictly confidential and will be shared only with you and within TrialNet.
Type 1 Diabetes
Currently, there is no cure for T1D, but researchers are actively searching for one.
At this time, there is no way to reverse T1D. TrialNet is conducting clinical trials to find ways to slow down or stop disease progression.
Yes. Caucasians (white or of European origin) are at higher risk than people from other ethnic groups.